Loading…
LeonaBio, Inc. is projected to rise to $13.67 by 2027, a +39% move from its current price of $9.81. LONA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $9.38 | $9.82 | $10.27 | +0.05% |
| May 30 | $9.22 | $9.82 | $10.47 | +0.11% |
| May 31 | $9.09 | $9.83 | $10.62 | +0.16% |
| Jun 1 | $8.99 | $9.83 | $10.76 | +0.22% |
| Jun 2 | $8.90 | $9.84 | $10.88 | +0.27% |
| Jun 3 | $8.82 | $9.84 | $10.99 | +0.33% |
| Jun 4 | $8.74 | $9.85 | $11.09 | +0.38% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $8.74 | $9.85 | $11.09 | +0.38% |
| Week 2 | $8.35 | $9.89 | $11.70 | +0.77% |
| Week 3 | $8.08 | $9.92 | $12.19 | +1.15% |
| Week 4 | $7.85 | $9.96 | $12.64 | +1.54% |
| Week 5 | $7.66 | $10.00 | $13.05 | +1.93% |
| Week 6 | $7.50 | $10.04 | $13.43 | +2.32% |
| Week 7 | $7.36 | $10.08 | $13.80 | +2.71% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
LeonaBio, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. It was incorporated in 2011 and is headquartered in Bothell, Washington.
In January 2026, the company changed its name from Athira Pharma, Inc. to LeonaBio, Inc. Its lead products include lasofoxifene and ATH-1105, and the pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of diabetic neuropathy, which is in phase 1 clinical trial; and ATH-1017 for the treatment of Alzheimer's disease and Parkinson's disease, which is in phase 2 clinical trial, as well as early compounds which are in preclinical phase.
LeonaBio, Inc. (LONA) is currently priced at $10.33 with a market cap around $97.04M and is ranked 4245 by market capitalization. The stock trades in the Healthcare sector. The current price sits within a multi-year framework that the forecast projects to move higher over time, with notable upside potential in later years.
A major floor 55.8% below — a decisive break under it would weaken the trend.
The nearest floor, 16.1% below — buyers have tended to step in here.
The nearest ceiling, 14.8% above — a clean break opens room to run.
A major ceiling 30.4% above — clearing it would confirm fresh momentum.
Key LONA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LONA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $9.90 | Sell | $9.94 | Sell |
| MA 10 | $10.23 | Sell | $10.00 | Sell |
| MA 20 | $9.88 | Sell | $9.87 | Sell |
| MA 50 | $9.68 | Buy | $9.21 | Buy |
| MA 100 | $7.74 | Buy | $8.11 | Buy |
| MA 200 | $6.04 | Buy | $7.08 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.67 | Neutral |
| Stoch RSI (14) | 7.03 | Buy |
| CCI (20) | -10.69 | Neutral |
| Williams %R (14) | -88.41 | Info |
| MACD (12,26,9) | -0.07 | Sell |
| ROC (12) | -2.29 | Sell |
| Bollinger %B (20,2) | 0.47 | Neutral |
| Stochastic %K (14) | 11.59 | Buy |
| TRIX (15) | 0.43 | Buy |
| Awesome (5,34) | 0.37 | Buy |
| Ultimate (7,14,28) | 39.16 | Neutral |
| Momentum (10) | -0.36 | Sell |
| Aroon Osc (25) | 60.00 | Buy |
| Hull MA (9) | 9.80 | Buy |
| ADX (14) | 11.97 | Neutral |
| ATR (14) | 0.38 | Info |
The 30-day technical picture is described as BULLISH, with RSI(14) at 60. The 50-day simple moving average is $9.62 and the 200-day simple moving average is $5.98, indicating a near-term bullish tilt. Support is at $8.23 and resistance at $11.26, framing a near-term trading range.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.34 | $9.81 | $14.65 | 0% | Neutral | |
| $10.16 | $13.67 | $19.81 | +39% | Bullish | |
| $10.48 | $14.80 | $22.63 | +51% | Bullish | |
| $11.25 | $16.55 | $26.39 | +69% | Bullish | |
| $10.67 | $16.28 | $26.88 | +66% | Bullish | |
| $11.76 | $18.59 | $31.64 | +89% | Bullish | |
| $16.41 | $26.80 | $46.86 | +173% | Bullish | |
| $17.97 | $30.27 | $54.22 | +209% | Bullish | |
| $20.09 | $34.88 | $63.90 | +256% | Bullish | |
| $22.39 | $40.02 | $74.84 | +308% | Bullish | |
| $34.05 | $69.92 | $142.33 | +613% | Bullish | |
| $51.52 | $114.49 | $262.91 | +10.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $4.34 | $9.81 | $11.63 | +0.00% |
| June 2026 | $8.26 | $9.84 | $12.10 | +0.33% |
| July 2026 | $8.54 | $10.31 | $12.95 | +4.75% |
| August 2026 | $8.86 | $10.82 | $13.82 | +4.95% |
| September 2026 | $8.55 | $10.54 | $13.65 | -2.55% |
| October 2026 | $8.27 | $10.28 | $13.46 | -2.53% |
| November 2026 | $8.56 | $10.72 | $14.19 | +4.29% |
| December 2026 | $8.69 | $10.96 | $14.65 | +2.27% |
Click any year to see its month-by-month LONA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, LONA is projected to trade between $4.34 and $14.65, averaging $9.81 — a potential gain of 0% from today's $9.81. A consolidation phase looks the most probable path here.
LeonaBio, Inc.'s 2027 outlook centres on $13.67, within a $10.16 to $19.81 range. That is up +39% on the projected 2026 average. That marks a +39% change versus current levels. Momentum favours further upside here.
By 2028, LONA could reach as high as $22.63, with a base case around $14.80 and support toward $10.48 — roughly +51% from $9.81. Buyers look set to stay in control over this stretch.
Expect LONA to range from $11.25 to $26.39 through 2029. The $16.55 average target implies a +69% move from current prices. That is up +12% on the projected 2028 average. Momentum favours further upside here.
The LONA price prediction for 2030 points to an average of $16.28 (low $10.67, high $26.88) — a potential gain of +66% on today's $9.81. Buyers look set to stay in control over this stretch.
In 2031, LONA is projected to trade between $11.76 and $31.64, averaging $18.59 — a potential gain of +89% from today's $9.81. That is up +14% on the projected 2030 average. Momentum favours further upside here.
LeonaBio, Inc.'s 2032 outlook centres on $26.80, within a $16.41 to $46.86 range. That is up +44% on the projected 2031 average. That marks a +173% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, LONA could reach as high as $54.22, with a base case around $30.27 and support toward $17.97 — roughly +209% from $9.81. Momentum favours further upside here.
Expect LONA to range from $20.09 to $63.90 through 2034. The $34.88 average target implies a +256% move from current prices. That is up +15% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The LONA price prediction for 2035 points to an average of $40.02 (low $22.39, high $74.84) — a potential gain of +308% on today's $9.81. Momentum favours further upside here.
In 2040, LONA is projected to trade between $34.05 and $142.33, averaging $69.92 — a potential gain of +613% from today's $9.81. That is up +75% on the projected 2035 average. Buyers look set to stay in control over this stretch.
LeonaBio, Inc.'s 2050 outlook centres on $114.49, within a $51.52 to $262.91 range. That is up +64% on the projected 2040 average. That marks a +10.7x change versus current levels. Momentum favours further upside here.
Investing $1,000 in LONA today (≈ 101.936799 LONA) could be worth
$11,670.55
+$10,670.55 (+1067%) by 2050 · US Dollar
Based on the average projected LONA price of $114.49 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LONAwould be worth at today's price.
$1,000 invested in LONA on May 27, 2025 (≈ 348.43207 LONA) would be worth
$3,418.12
+$2,418.12 (+241.8%) today · 3.42× · US Dollar
Based on a LONA entry price of $2.87 vs. today's $9.81.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $9.62 | $1,019.75 | +2.0% |
| 1 month ago | $8.35 | $1,174.85 | +17.5% |
| 3 months ago | $5.62 | $1,745.55 | +74.6% |
| 6 months ago | $4.35 | $2,255.17 | +125.5% |
| 1 year ago | $2.87 | $3,418.12 | +241.8% |
| All time (5.0y) ago | $188.6 | $52.01 | -94.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LONA forecast.
Our base-case forecast reaches $20.00 around 2032.
Implied market cap at $20.00: $187.87M
The multi-year forecast shows substantial upside potential beyond the near term. The 2027 average price is $14.46 with a bullish sentiment and a 39.9% anticipated ROI, followed by higher forecasts in subsequent years. The 2030 average price is $17.30 with a 67.5% ROI and bullish sentiment.
The forecast progresses to 2032 average $28.76 (178.4% ROI), 2033 $32.61 (215.7%), 2034 $37.81 (266%), and 2035 $42.99 (316.2%), all with bullish sentiment. The long horizon sees the average price climb to $76.69 by 2040 (642.4% ROI) and to $123.41 by 2050 (1094.6% ROI), maintaining a bullish outlook with corresponding upside potential and inherent uncertainty. The drivers behind these projections include the company’s clinical-stage pipeline across multiple programs (ALS, diabetic neuropathy, Alzheimer's and Parkinson's) and ongoing preclinical efforts, though outcomes depend on trial results and regulatory approvals.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $17.30, with a low of $11.27 and a high of $28.72, and a forecasted ROI of 67.5% with bullish sentiment.
Forecasts show bullish sentiment from 2027 onward with rising average prices through 2050, though 2026 is neutral. These are estimates and not guarantees, and investors should consider the inherent risks.
According to the forecast, the 2032 maximum is $50.57 and the 2033 maximum is $58.77, indicating a $50 level could be reached in the 2032–2033 window in the high scenario.
The projections are anchored in the company’s clinical-stage pipeline, including ATH-1105 for ALS (phase 1), ATH-1020 for diabetic neuropathy (phase 1), ATH-1017 for Alzheimer's and Parkinson's (phase 2), and other preclinical programs.
The 2050 forecast shows an average price of $123.41, with a low of $55.53 and a high of $283.83, and a forecasted ROI of 1094.6% with bullish sentiment.
LeonaBio, Inc. Community Discussion
0Share your LeonaBio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.